Want to see KYNB full AI Analyst Report?
KYNB Stock Chart & Stats
$7.95
>-$0.01(-1.28%)
At close: 4:00 PM EST
$7.95
>-$0.01(-1.28%)
Day’s Range― - ―
52-Week Range$4.32 - $11.39
Previous CloseN/A
VolumeN/A
Average Volume (3M)25.61K
Market Cap
$19.11M
Enterprise Value-$38.76M
Total Cash (Recent Filing)$91.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)<0.1
Beta0.69
Next Earnings
Nov 09, 2026EPS Estimate
-3.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)58.19
Shares Outstanding4,049,124
10 Day Avg. Volume24,499
30 Day Avg. Volume25,615
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.18
Price to Sales (P/S)5.51
P/FCF Ratio-7.38
Enterprise Value/Market Cap-2.03
Enterprise Value/Revenue-8.39
Enterprise Value/Gross Profit-46.25
Enterprise Value/Ebitda0.41
Forecast
1Y Price Target
$38.50Price Target Upside384.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-8.66
Revenue Forecast (FY)$6.42M
Bulls Say, Bears Say
Bulls Say
Cash RunwayThe stated cash runway into 2028 gives Kyntra time to advance its clinical programs without an immediately pressing financing event. This supports milestone execution and preserves strategic flexibility, although continued spending means the runway depends on disciplined cash management.
Clinical Pipeline ProgressA defined Phase II study with active enrollment, multiple dose levels, and a near-term interim analysis creates a measurable path toward clinical validation. Progress in this program could strengthen partnering prospects and establish a clearer development trajectory for the oncology pipeline.
Liability ReductionLower future payment obligations improve the company’s financial flexibility and reduce the burden placed on future royalty streams. The revised financing structure also allows Kyntra to retain subsequent royalties after the capped obligation is satisfied, supporting longer-term cash generation potential.
Bears Say
Revenue ContractionSustained revenue contraction weakens the operating base supporting Kyntra’s research platform and increases reliance on financing, royalties, or successful product development. The sharp gross-margin deterioration and continuing operating losses also make reported earnings less representative of durable business performance.
Cash Burn And Negative EquityOngoing cash consumption and a negative equity position limit financial resilience even after debt fell to zero. Continued investment in clinical programs may require substantial funding, while weak cash conversion reduces the company’s ability to support operations internally over the medium term.
Nasdaq Listing UncertaintyThe pending delisting appeal creates a structural corporate and financing risk rather than a temporary market fluctuation. Losing the Nasdaq listing could reduce market access, complicate future capital raising, and weaken institutional participation while compliance remains unresolved.
Kyntra Bio News
KYNB FAQ
What was Kyntra Bio’s price range in the past 12 months?
Kyntra Bio lowest stock price was $4.32 and its highest was $11.39 in the past 12 months.
What is Kyntra Bio’s market cap?
Kyntra Bio’s market cap is $19.11M.
When is Kyntra Bio’s upcoming earnings report date?
Kyntra Bio’s upcoming earnings report date is Nov 09, 2026 which is in 11 days.
How were Kyntra Bio’s earnings last quarter?
Kyntra Bio released its earnings results on Aug 13, 2026. The company reported $2.96 earnings per share for the quarter, beating the consensus estimate of -$3.184 by $6.144.
Is Kyntra Bio overvalued?
According to Wall Street analysts Kyntra Bio’s price is currently Undervalued.
Does Kyntra Bio pay dividends?
Kyntra Bio does not currently pay dividends.
What is Kyntra Bio’s EPS estimate?
Kyntra Bio’s EPS estimate is -3.55.
How many shares outstanding does Kyntra Bio have?
Kyntra Bio has 4,049,124 shares outstanding.
What happened to Kyntra Bio’s price movement after its last earnings report?
Kyntra Bio reported an EPS of $2.96 in its last earnings report, beating expectations of -$3.184. Following the earnings report the stock price went up 0.142%.
Which hedge fund is a major shareholder of Kyntra Bio?
Currently, no hedge funds are holding shares in KYNB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kyntra Bio
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
KYNB Company Deck
KYNB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful clinical and operational positives: concrete Phase I/IST efficacy signals for FG-3246 (with a clear plan for a Phase II interim readout in Q4 2026), a finalized Phase III protocol and compelling subgroup data for roxadustat, a unique non-PSMA therapeutic + companion diagnostic position, and a positive swing to net income with a cash runway into 2028. Offsetting these were notable near-term financial headwinds (negative reported revenue and higher operating expenses), safety and biomarker confirmation risks that require larger data sets, enrollment and market dynamics uncertainty (Pluvicto adoption) and the dependence on partnering/capital for a registrational path for roxadustat. On balance, the highlights modestly outweigh the lowlights due to actionable clinical progress and a forthcoming near-term catalyst (FG-3246 interim) alongside sufficient cash runway to advance programs.View all KYNB earnings summariesKYNB Stock 12 Month Forecast
Average Price Target
$38.50
▲(384.28% Upside)
Technical Analysis
Ownership Overview
3.37% Insiders
22.63% Mutual Funds
0.01% Other Institutional Investors
70.13% Public Companies and
Individual Investors